Table 1 Serum OX40L and characteristics of subjects from SSA, SRA and control group

Cases

130

110

82

Age (years)

6.78 ± 1.73

6.95 ± 1.72

7.01 ± 1.80

Gender (Male/Female)

67 (51.5%)

55 (50%)

42 (51.2%)

Atopic subjects

0

67 (60.9%)

48 (58.5%)

Serum IgE (IU/mL)

76.6 ± 14.4

281.5 ± 31.4*

292.2 ± 34.0*#

Eosinophil count (cells/mm³)

256.9 ± 50.7

597.1 ± 101.3*

630.5 ± 111.9*#

Eosinophils (%)

3.78 ± 0.75

7.66 ± 1.30*

8.08 ± 1.43*#

Neutrophil count (cells/mm³)

3749.8 ± 587.6

5073.9 ± 715.1*

5375.2 ± 743.8*#

Neutrophils (%)

55.14 ± 8.64

65.05 ± 9.17*

68.91 ± 9.54*#

Monocyte count (cells/mm³)

406.6 ± 91.7

529.3 ± 122.0

526.9 ± 136.5

Monocytes (%)

5.98 ± 1.35

6.79 ± 1.56

6.76 ± 1.75

Lymphocyte count (cells/mm³)

2626.3 ± 591.7

2370.0 ± 521.3*

2161.3 ± 423.9*#

Lymphocytes (%)

38.62 ± 8.70

30.39 ± 6.68*

27.71 ± 5.44*#

ACT score

25

16.82 ± 3.27*

13.98 ± 3.22*#

FEV1% predicted

99.2 ± 3.5

71.0 ± 9.3*

67.6 ± 9.5*#

IL-6 (pg/mL)

3.95 ± 0.72

6.94 ± 1.37*

8.24 ± 1.28*#

TSLP (pg/mL)

89.1 ± 12.1

223.2 ± 24.9*

244.5 ± 33.6*#

Serum OX40L (pg/mL)

238.6 ± 27.8

655.6 ± 138.8*

791.2 ± 167.9*#